mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Shiheido, Hirokazu ^a   Takashima, Hideaki ^a   Doi, Nobuhide ^a   Yanagawa, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; SCAFFOLD PROTEIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MDM2 PROTEIN, HUMAN; PEPTIDE; PEPTIDE LIBRARY;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA LIBRARY; HUMAN; HUMAN CELL; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT; TUMOR GROWTH; ADENOVIRUS; AMINO ACID SEQUENCE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IC 50; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRIDAE; AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GREEN FLUORESCENT PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952668642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017898     Document Type: Article

References (42)

1. Chene P, (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109.
2. Meek DW, (2009) Tumor suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.
3. Shangary S, Wang S, (2008) Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 14: 5318-5324.
4. Wasylyk C, Salvi R, Argentini M, Dureuil C, Abecassis J, et al. (1999) p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18: 1921-1934.
5. Chene P, (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109.
6. Toledo F, Wahl GM, (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923.
7. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, et al. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48: 909-912.
8. Hainaut P, Hollstein M, (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77: 81-137.
9. Levine AJ, (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
10. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
11. Chene P, Fuchs J, Carena I, Furet P, Garcia C, et al. (2002) Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett 529: 293-297.
12. Hu B, Gilkes DM, Chen J, (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67: 8810-8817.
13. Shangary S, Qin D, McEachern D, Liu M, Miller RS, et al. (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 105: 3933-3938.
14. Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, et al. (2008) Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 7: 1533-1542.
15. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP, (2009) Awakening guardian angel: drugging the p53 pathway. Nat Rev Cancer 9: 862-873.
16. Blagosklonny MV, (2002) P53: an ubiquitous target of anticancer drugs. Int J Cancer 98: 161-166.
17. Chen F, Wang W, El-Deiry WS, (2010) Current strategies to target p53 in cancer. Biochem Pharmacol 80: 724-30.
18. Borghouts C, Kunz C, Groner B, (2005) Current strategies for the development of peptide-based anti-cancer therapeutics. J Peptide Sci 11: 713-726.
19. Guarracino DA, Arora PS, (2009) Making strides in peptide-based therapeutics. Chem Biol 16: 919-920.
20. Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, et al. (1996) Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141-2147.
21. Pazgier M, Liu M, Zou G, Yuan W, Li C, et al. (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 106: 4665-4670.
22. Nemoto N, Miyamoto-Sato E, Husimi Y, Yanagawa H, (1997) In vitro virus: Bonding of mRNA bearing puromycin at the 3′-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro. FEBS Lett 414: 405-408.
23. Roberts RW, Szostak JW, (1997) RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc Natl Acad Sci U S A 94: 12297-12302.
24. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moerau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
25. Puig O, Caspary F, Rigaut G, Rutz B, Bouveret E, et al. (2001) The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 24: 218-229.
26. Phan J, Li Z, Kasprzak A, Li B, Sebti S, et al. (2010) Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem 285: 2174-2183.
27. Kallen J, Goepfert A, Blechschmidt A, Izaac A, Geiser M, et al. (2009) Crystal structures of human MdmX (Hdmx) in complex with p53 peptide analogues reveal surprising conformational changes. J Biol Chem 284: 8812-8821.
28. Kanovsky M, Raffo A, Drew L, Rosal R, Do T, et al. (2001) Peptides from the amino terminal mdm2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci U S A 98: 12438-12443.
29. Rosal R, Brandt PB, Pincus MR, Wang H, Mao Y, et al. (2005) The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev 57: 653-660.
30. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, et al. (1997) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 7: 860-869.
31. Matsuura T, Yomo T, (2006) In vitro evolution of proteins. J Biosci Bioeng 101: 449-456.
32. Zondlo SC, Lee AE, Zondlo NJ, (2006) Determination of specificity of MDM2 for the activation domains of p53 and p65: Proline27 disrupts the MDM2-binding motif of p53. Biochemistry 45: 11945-11957.
33. Wade M, Wang YV, Wahl GM, (2010) The p53 orchestra: MDM2 and MDMX set the tone. Trends Cell Biol 20: 299-308.
34. Jackson MW, Lindstrom MS, Berberich SJ, (2001) MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J Biol Chem 276: 25336-25341.
35. Kawakami T, Ohta A, Ohuchi M, Ashigai H, Murakami H, et al. (2009) Diverse backbone-cyclized peptides via codon reprogramming. Nat Chem Biol 5: 888-890.
36. Frankel A, Millward SW, Roberts RW, (2003) Encodamers: unnatural peptide oligomers encoded in RNA. Chem Biol 10: 1043-1050.
37. Josephson K, Hartman MC, Szostak JW, (2005) Ribosomal synthesis of unnatural peptides. J Am Chem Soc 127: 11727-11735.
38. Murakami H, Ohta A, Ashigai H, Suga H, (2006) A highly flexible tRNA acylation method for non-natural polypeptide synthesis. Nat Methods 3: 357-359.
39. Miyamoto-Sato E, Takashima H, Fuse S, Sue K, Ishizaka M, et al. (2003) Highly stable and efficient mRNA templates for mRNA-protein fusions and C-terminal labeled proteins. Nucleic Acids Res 31: e78.
40. Sawasaki T, Ogasawara T, Morishita R, Endo Y, (2002) A cell-free protein synthesis system for high-throuput proteomics. Proc Natl Acad Sci U S A 99: 14652-14657.
41. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T, (2001) Design of the linker which effectively separate domains of a bifunctional fusion protein. Protein Eng 14: 529-532.
42. Matsumura N, Tsuji T, Sumida T, Kokubo M, Onimaru M, et al. (2010) mRNA display selection of a high-affinity, Bcl-XL-specific binding peptide. FASEB J 24: 2201-2210.